Skip to main content
Equibles

Barrett Evans

Board Member

Protagenic Therapeutics, Inc.\new (PTIX)

CEO

Protagenic Therapeutics, Inc.\new (PTIX)

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Barrett Evans

Barrett Evans is recorded as Board Member and CEO at Protagenic Therapeutics, Inc.\new (PTIX). Protagenic Therapeutics, Inc.\new reported in an 8-K filed August 13, 2025 that Barrett Evans was terminated as Chief Executive Officer and President, effective August 8, 2025. Protagenic Therapeutics, Inc.\new reported in an 8-K filed May 19, 2025 that Barrett Evans was appointed director of the Company, effective May 15, 2025. Protagenic Therapeutics, Inc.\new reported in an 8-K filed May 19, 2025 that Barrett Evans was appointed President and Chief Executive Officer, effective May 15, 2025.

“On August 8, 2025, in connection with the Restructuring Plan, the Board a terminated the employment of (i) Barrett Evans as Chief Executive Officer and President and (ii) Colin Stott as Chief Operating Officer, in each case effective immediately.”
Protagenic Therapeutics, Inc.\new Form 8-K, filed August 13, 2025 · Read the filing
“appointed Barrett Evans as President and Chief Executive Officer, and a director of the Company, Colin Stott as Chief Operating Officer and as a director of the Company, and Jennifer Chao as a director of the Company, in each case effective immediately after the Closing on May 15, 2025”
Protagenic Therapeutics, Inc.\new Form 8-K, filed May 19, 2025 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

Company network

Recorded roles and call appearances connecting this person to public companies.

Leadership on record at Protagenic Therapeutics, Inc.\new

Other people whose current roles at this company are on record from its filings.

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.